Publications and Presentations

PUBLICATIONS AND PRESENTATIONS 2018/19

Publications

SORCE Kidney Cancer 2 (2018) 123–131. doi: 10.3233/KCA-180038 16 July, 2018 What survival benefits are needed to make Adjuvant Sorafenib worthwhile after resection of intermediate – or high-risk renal cell carcinoma? Clinical investigators’ preferences in the SORCE Trial .

P3BEP Journal of Clinical Oncology P3BEP (ANZUP 1302): An international randomised phase III trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumors (GCTs) . Alison Yan Zhang, Guy C . Toner, Nicola Jane Lawrence, Martin R . Stockler, Andrew James Martin, Kate Ford, Amanda Gwendolyn Stevanovic, David Wyld, Euan Thomas Walpole, Simon Troon, Fritha J . Hanning, Girish Mallesara, Andrew James Weickhardt, Alison Jane Birtle, Ian D . Davis, Peter S . Grimison .

BJU, January 2019 Chiong E, Murphy DG, Akaza H, Buchan NC, Chung BH, Kanesvaran R, Khochikar M, Letran J, Lojanapiwat B, Ng CF, Ong T, Pu YS, Saad M, Schubach K, Türkeri L, Umbas R, Le Chuyen V, Williams S, Ye DW; ANZUP Cancer Trials Group, Davis ID . Management of patients with advanced prostate cancer in the Asia Pacific region: ‘real-world’ consideration of results from the Advanced Prostate Cancer Consensus Conference (APCCC) 2017 . BJU Int . 2019;123(1):22-34 . doi: 10 .1111/bju .14489 .

Lancet Oncology, October 2018 Williams S . GDPR – not just an EU regulation? Lancet Oncol . 2018;19(10):e508 . doi: 10 .1016/S14702045(18)30696-X .

TheraP BJUI, submitted March 2019 Michael S . Hofman, Louise Emmett, John Violet, Alison Zhang, Nicky J . Lawrence, Martin Stockler, Roslyn J . Francis, Amir Iravani, Scott Williams , Arun Azad, Andrew Martin, Margaret McJannett, ANZUP TheraP team, Ian D . Davis . A randomised phase 2 trial of 177Lu-PSMA-617 theranostic versus cabazitaxel in progressive metastatic castration resistant prostate cancer: (ANZUP 1603) .

ENZAMET ASCO, late breaking abstract submitted March 2019 Overall survival (OS) results of a phase III randomized trial of standard-of-care therapy with or without enzalutamide for metastatic hormone-sensitive prostate cancer (mHSPC): ENZAMET (ANZUP 1304) .

ENZAMET NEJM, submitted March 2019 Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer .

P3BEP (ANZUP 1302) Journal of Clinical Oncology An international randomized phase III trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumors (GCTs) . Alison Yan Zhang, Guy C . Toner, Nicola Jane Lawrence, Martin R . Stockler, Andrew James Martin, Kate Ford, Amanda Gwendolyn Stevanovic, David Wyld, Euan Thomas Walpole, Simon Troon, Fritha J . Hanning, Girish Mallesara, Andrew James Weickhardt, Alison Jane Birtle, Ian D . Davis, Peter S . Grimison .

TheraP Journal of Clinical Oncology A randomized phase II trial of [177Lu]PSMA-617 theranostic versus cabazitaxel in progressive metastatic castrationresistant prostate cancer . Michael Hofman, Louise Emmett, John A Violet, Nicola Jane Lawrence, Scott Williams, Martin R . Stockler, Roslyn J Francis, Amir Iravani, Alison Yan Zhang, Andrew James Martin, Arun Azad, Sonia Yip, Ailsa Langford, Margaret Mary McJannett, Ian D . Davis .

Presentations

BL.12 ASCO, 1-5 June, 2018 Srikala S Sridhar et al . Abstract #219679 CCTG BL12: Randomized phase II trial comparing nab-paclitaxel (Nab-P) to paclitaxel (P) in patients (pts) with advanced urothelial cancer progressing on or after a platinum containing regimen . 2018 American Society of Clinical Oncology (ASCO) Annual Meeting, McCormick Place, Chicago, IL, USA .

P3BEP ASCO, 1-5 June, 2018 M . Stockler, et al . The ANZUP Phase 3 Accelerated BEP trial: A randomised phase 3 trial of accelerated versus standard BEP chemotherapy for patients with intermediate and poor-risk metastatic germ cell tumours . ASCO . Chicago, USA .

P3BEP 3rd AYA congress, 4-6 December, 2018 Crossing the paediatric and adult hospital divide: An international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumours .

P3BEP ASCO GU, 14-16 February 2019 An international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumours: P3BEP (ANZUP 1302) .

TheraP ASCO GU, 14 February 2019 TheraP: A randomized phase II trial of [177Lu]-PSMA-617 theranostic versus cabazitaxel in progressive metastatic castration-resistant prostate cancer .

Dr Simeon Ngweso – Villas Marshall Prize Winner USANZ ASM 2019 Penile cancer in Western Australia: “Discrepancies in registry Coding for Penile cancer” and “The significance of demographic location in survival outcomes” .